Drug
Itacitinib
Status:
Phase 2
Condition:
Lung Transplant
Intervention Type:
Oral Drug
Funder Type:
Industry
Drug Details
Itacitinib is a novel and selective JAK1 inhibitor.
Study Purpose
The purpose of this study is to evaluate the safety, efficacy, pharmacokinetics, and pharmacodynamics of itacitinib in participants with post-lung transplant bronchiolitis obliterans syndrome (BOS).
Find a Clinical Trial